Chee Soon-Phaik, Jap Aliza, Bacsal Kristine
Singapore National Eye Centre, Singapore.
Am J Ophthalmol. 2009 Jan;147(1):154-161.e1. doi: 10.1016/j.ajo.2008.07.044. Epub 2008 Oct 2.
To determine prognostic factors of Vogt-Koyanagi-Harada disease (VKH).
Retrospective noninterventional.
Chart review of VKH patients of Singapore National Eye Centre for age at onset (age), gender, race, presenting visual acuity (VA) and VA at one month after starting treatment, severity of inflammation, treatment regime, and hearing loss. Outcome measures were: VA, persistent inflammation, cataracts, glaucoma, macular lesions, chorioretinal degeneration, and vitiligo at three years after onset.
There were 134 eyes of 67 patients. Majority were Chinese (n = 53, 79.1%) and female (n = 40, 59.7%). Median duration of follow-up was 9.1 years (range, 3.0 to 53.6 years). Median age was 42.3 years (range, 5.4 to 70.9 years). Main prognostic factors were VA at one month, age, and treatment regime. Good VA at one month was associated with greater likelihood of good VA at three years (odds ratio [OR], 43.9; P = .02), less persistent inflammation (OR, 0.5; P = .006), cataract (OR, 0.10; P = .01), and chorioretinal degeneration (OR, 0.2; P = .04). Older age was associated with higher likelihood of cataract (OR, 1.1; P = .02), chorioretinal degeneration (OR, 1.1; P = .03), and vitiligo (OR, 1.1; P = .004). Early treatment with high-dose systemic corticosteroids resulted in less persistent inflammation (OR, 0.2; P = .04). Late high corticosteroid treatment was associated with greater risk of cataract (OR, 9.6; P = .03).
Good VA at one month, younger age at onset, and early treatment with high-dose corticosteroids were associated with better outcomes.
确定伏格特-小柳-原田病(VKH)的预后因素。
回顾性非干预性研究。
对新加坡国家眼科中心的VKH患者病历进行回顾,内容包括发病年龄、性别、种族、初诊视力及开始治疗后1个月时的视力、炎症严重程度、治疗方案和听力损失情况。观察指标为发病3年后的视力、持续性炎症、白内障、青光眼、黄斑病变、脉络膜视网膜变性和白癜风。
共67例患者的134只眼。大多数为华裔(n = 53,79.1%),女性居多(n = 40,59.7%)。中位随访时间为9.1年(范围3.0至53.6年)。中位年龄为42.3岁(范围5.4至70.9岁)。主要预后因素为1个月时的视力、年龄和治疗方案。1个月时视力良好与3年后视力良好的可能性更大相关(优势比[OR],43.9;P = 0.02),持续性炎症较少(OR,0.5;P = 0.006),白内障发病率较低(OR,0.10;P = 0.01),脉络膜视网膜变性发病率较低(OR,0.2;P = 0.04)。年龄较大与白内障(OR,1.1;P = 0.02)、脉络膜视网膜变性(OR,1.1;P = 0.03)和白癜风(OR,1.1;P = 0.004)的发病可能性较高相关。早期使用高剂量全身糖皮质激素治疗可减少持续性炎症(OR,0.2;P = 0.04)。晚期大剂量糖皮质激素治疗与白内障风险增加相关(OR,9.6;P = 0.03)。
1个月时视力良好、发病年龄较小以及早期使用高剂量糖皮质激素治疗与更好的预后相关。